unseasoned Cancer Treatment Brings Hope in 2001 by liza Jane Maltin
On May 10 2001, FDA approved a new dose known as Gleevec ( pull inerly St1- 571) for successfully treating cancer of the white parentage cells known as chronic myelogenous leukemia (CML) and a rare form of cancer that affects the stomach and intestines called gastrointestinal stromal tumors (GIST).
According to Michael Heinrich, MD, an associate professor of medicine at Oregon Health Sciences University in Portland and a division of the team that developed Gleevec, conventional leukemia therapy like chemotherapy and radiation, kill perverted marrow cells, but also destroy healthy ones and thereof extremely difficult to tolerate. Gleevec, on the other hand, selectively tar conk outs an atypical cancer - causing protein called BCR-ABL, which causes the cancerous white blood cells to get down out of control.
Research is underway to test Gleevecs effectiveness against some kinds of brain, lung, prostate, colorectal and pancreatic cancers.
Heinrich is optimistic about the preliminary results and predicts fundamental changes non only in how we treat cancer, but also in the very way we think and talk about it.
Works Citied
Maltin Jane Liza, New Cancer Treatment Brings Hope in 2001. WebMD Health, Dec. 26, 2001
If you want to get a full information about our service, visit our page: How it works.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.